ISSN: 1470-2045

The Lancet Oncology Q1 Unclaimed

Lancet Publishing Group United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Oncology is a journal indexed in SJR in Oncology with an H index of 324. Journal with a Single blind Peer Review review system, and It has a price of 2395 €. The scope of the journal is focused on Oncology, Cancer,. It has an SJR impact factor of 13,53 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 13,53.

The Lancet Oncology focuses its scope in these topics and keywords: cancer, phase, patients, randomised, openlabel, care, advanced, metastatic, multicentre, doubleblind, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Oncology (Q1)

Price

2395 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

13,53

SJR Impact factor

324

H Index

491

Total Docs (Last Year)

1722

Total Docs (3 years)

6955

Total Refs

15824

Total Cites (3 years)

575

Citable Docs (3 years)

8,9

Cites/Doc (2 years)

14,16

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

JAMA oncology Q1
Annals of Oncology Q1
Molecular Cancer Q1
CA - A Cancer Journal for Clinicians Q1
Cancer Discovery Q1

Compare this journals

Aims and Scope

Best articles by citations

New screening test for colorectal cancer gets off to a good start

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial

Household surfaces hide secondhand smoke affecting children

An extra defence against skin cancer?

Nature Reviews Cancer online

Australian cancer survival figures greatly improved

FDA licences imatinib mesylate for CML

Interactive

New nerve-block analgesia for patients with pancreatic cancer

Intracellular fusion antibodies may be suicide for cancer cells

EPA halts cancer-induced weight loss

Allan van Oosterom, President of the EORTC

SHOW MORE ARTICLES

Amgen's point of view on epoetins

Improving and maintaining human health

Lymphatic entrapment of tumour cells after sentinel lymph-node biopsy for melanoma

Cancer Institute at Chennai: a model for resource-poor countries

Electrolysis being trialled for use in liver cancer

CCI-779: a new targeted anticancer agent

Why do hypoxic cells behave badly?

Correlation of MRI/PET rim enhancement in breast cancer: a delivery related phenomenon with therapy implications?

Low susceptibility genes for breast cancer: the way forward?

Oncology and the media

Is red tape stifling the progress of new anticancer drugs?